CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
VP-102 with applicatorcombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03186378
NCT03186378Phase 2Completed
CompareCT.gov

A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of VP-102 Topical Film Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum

Verrica Pharmaceuticals Inc.·interventional·Posted Jun 14, 2017·Updated Aug 11, 2021

In Brief

A Phase 2 clinical trial evaluating VP-102 with applicator for Molluscum Contagiosum. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The primary objective of the study is to determine the presence or absence of systemic cantharidin exposure from a single 24-hour dermal application of VP-102 topical film-forming solution \[0.7% (w/v) cantharidin\] (VP-102) when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older. Treatment will continue over the course of 3 additional 21 day intervals allowing for further evaluation of safety, efficacy and impact on quality of life.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMolluscum Contagiosum
CountriesUnited States
CollaboratorsPaidion Research, Inc., Database Integrations, Inc., Cato Research, Instat Services

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 14, 2017
Enrollment StartJun 8, 2017
Primary CompletionJun 25, 2018
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 9.0 years ago

Interventions

VP-102 with applicatorcombination

Subjects will receive treatment to their molluscum contagiosum with VP-102.